




Annals of Oncology

Official Journal of the
European Society for Medical Oncology

Volume 13, 2002 Supplement 2



8th International Conference on Malignant
Lymphoma

12–15 June, 2002: Lugano, Switzerland

PARTICIPANTS ARE CREDITED WITH 25 POINTS
ESMO-MORA CATEGORY I

OXFORD
UNIVERSITY PRESS

GLIVEC: 100 mg Hard Capsules. Imatinib mesilate. Capsules containing 100 mg of imatinib as mesilate. **Indications:** Treatment of patients with chronic myeloid leukaemia (CML) in blast crisis, accelerated phase or in chronic phase after failure of interferon- α therapy. **Dosage:** 400 mg a day for patients in chronic phase (CML) and 600 mg a day for patients in accelerated phase or blast crisis, administered orally, once daily. If severe non-haematologic adverse events develop, treatment must be withheld until the event has resolved. Treatment can be resumed at the same initial dose or at a reduced dose of 300 or 400 mg as appropriate. No dose adjustment because of blood cytopenias should be made within the first month of treatment. Thereafter, dose reduction or treatment interruption are recommended. Dose increase to 600 mg in patients with chronic phase disease or 800 mg in patients in accelerated phase or blast crisis if no haematologic or cytogenetic response is seen after 3 or 12 months, respectively or either increase of disease progression. **Contraindications:** Hypersensitivity to imatinib or to any of the excipients. **Precautions/Warnings:** Should be taken with food and a large glass of water to minimise the risk of gastrointestinal disturbances. Caution in patients with hepatic impairment. Beware of severe fluid retention. It is recommended that patients be weighed regularly. Regular monitoring of complete blood counts and liver function tests. No experience in children. Should not be used during pregnancy unless clearly necessary. Should not be used by breastfeeding mothers. **Interactions:** Caution with concomitant use of drugs inhibiting or inducing CYP3A4 (e.g. ketoconazole, dexamethasone) or being substrates of CYP3A4 (e.g. paracetamol) or CYP2D6. **Adverse reactions:** very frequent: oedema, fluid retention, neutropenia, thrombocytopenia or anaemia, headache, nausea, vomiting, diarrhoea, dyspepsia, dyspnoea, dermatitis, eczema, rash, muscle spasm and cramps, myalgia, joint swelling. **Packs:** Capsules of 100 mg, 120 List (KS). For detailed information, consult Arzneimittelkompendium der Schweiz, Veitshub, Novartis Pharma Schweiz AG, Stubbalmindstrasse, 4054, Postfach, 3001 Bern, Telefon 091 377 51 11.



target CML

 **NOVARTIS**
ONCOLOGY

www.novartispharma.ch

 **glivec**[®]
imatinib

precise targeting of the molecular
abnormality leading to CML

Table of Contents

Acknowledgements		v
Committees		
Financial Support		
Summary of Conference Schedule		vii
Conference Schedule		xi
Abstracts		
<i>Opening Ceremony</i>		
001	Henry Kaplan Memorial Lecture	1
<i>Oral Presentations</i>		
002–010	1. Molecular Heterogeneity and New Treatments in CLL	2
011–014	2. Waldenström's Macroglobulinemia	5
015–020	3. Biology of Marginal Zone B-Cell Lymphomas	6
021–027	4. What's New in Mantle Cell Lymphoma?	8
028–041	5. Biology of Lymphomas	10
042	6. Key Note Lecture I	14
043–047	7. Review Lectures	15
048–054	8. The Increasing Role of Prognostic Factors in the Choice of Treatment	17
055–056	9. Is There a Role for Allo-transplant in Any Type of Malignant Lymphomas?	19
057–063	10. Epidemiology, Imaging	20
064–068	11. Molecular Pathogenesis of Malignant Lymphomas: What's New?	22
069	12. Key Note Lecture II	24
070–086	13. Clinical Results in Lymphoma	25
087–096	14. Paediatric Lymphomas	29
097–105	15. Clinical Pathological Correlations	33
106	16. Minimal Residual Disease	36
107–117	17. New Chemotherapeutic Agents, New Modalities	37
118–123	18. Biological Therapies	40
124–131	20. Extranodal Lymphomas	42
<i>Posters</i>		
	Poster session I	
132–135	1. Imaging	44
136–147	2. Paediatric Lymphomas	45
148–174	3. Biology/Genetics	48
175–198	4. CLL/Myeloma/Indolent Lymphomas	55
199–216	5. Hodgkin's Disease	61
	Poster session II	
217–225	6. Epidemiology/Pathology	65
226–231	7. Minimal Residual Disease	69
232–263	8. Aggressive Lymphomas	71
264–279	9. Extranodal Lymphomas	79
280–301	10. New Treatments	83

<i>Further Abstracts</i>		
302–322	1. Epidemiology/Pathology	89
323–332	2. Imaging	95
333–377	3. Biology/Genetics	97
378–390	4. Paediatric Lymphomas	109
391–425	5. Hodgkin’s Disease	113
426–478	6. Extranodal Lymphomas	123
479–531	7. Indolent Lymphomas/Myeloma/CLL	137
532–591	8. Aggressive Lymphomas	151
592–611	9. New Treatments	166
612–631	10. Miscellaneous	171
Author Index		177
Subject Index		193
Abstracts of Satellite Symposia		201

Acknowledgements

Committees

Conference President

F. Cavalli, *Bellinzona, Switzerland*

International Organizing Committee

J.O. Armitage, *Omaha, USA*

B. Coiffier, *Pierre Bénite, France*

M. Ghielmini, *Bellinzona, Switzerland*

W. Hiddemann, *Munich, Germany*

T.A. Lister, *London, United Kingdom*

Scientific Advisory Board

F. Cabanillas, *Houston, USA*

G.P. Cannellos, *Boston, USA*

F.E. Cotter, *London, United Kingdom*

R. Dalla-Favera, *New York, USA*

V. Diehl, *Cologne, Germany*

R.I. Fisher, *Rochester, USA*

A. Hagenbeek, *Rotterdam, The Netherlands*

S.J. Horning, *Palo Alto, USA*

A. Lanzavecchia, *Bellinzona, Switzerland*

D.L. Longo, *Baltimore, USA*

E. Montserrat, *Barcelona, Spain*

S.B. Murphy, *Chicago, USA*

K. Rajewsky, *Cologne, Germany*

J.C. Reed, *La Jolla, USA*

M. Rozenzweig, *Princeton, USA*

H. Stein, *Berlin, Germany*

Local Organization and Conference Secretariat

O. Jackson, C. Brentan, A. Amato, *Lugano, Switzerland*

Financial Support

The conference organizers wish to thank the following sponsors for their financial support:

Main Sponsors

Amgen Europe

Baxter Oncology GmbH

Bioenvision Inc.

Chugai-Aventis France

City of Lugano

European School of Oncology

IDEC

Ligand & Elan Pharmaceuticals

Lilly Oncology

Novartis

Research Fund for WM, USA

Roche Ltd.

Sanofi-Synthelabo France

Schering AG

SuperGen, Inc.

Swiss League Against Cancer

Swiss Air Lines

Sponsors

Arcobaleno Transport

Astra Zeneca

Bristol-Myers Squibb CH

Cell Therapeutics Incorp.

Chiron Biopharmaceuticals USA

Ente Turismo Ticinese

Genitope Corp. USA

GlaxoSmithKline

Hans Huber Publisher

Janssen-Cilag

Lipomed

Lymphoma Research Foundation USA

Mundipharma

Pharmacia

Shire Pharmaceuticals

Annals of Oncology

Subscription information

A subscription to *Annals of Oncology* comprises 12 issues plus supplements, with an Annual Author and Keyword Index in each volume. Subscriptions are entered on a calendar year basis only. Please add sales tax to prices quoted. Price includes postage by surface mail or for subscribers in the USA and Canada by air freight or in India, Japan, Australia and New Zealand, by Air Speeded Post. Airmail rates are available on request.

Annual subscription rate (Volume 13, 2002)

Institutions/Individuals: Europe and UK £665.00, Rest of World US\$1090.00

Single issue: Europe and UK £70.00, Rest of World US\$114.00

Orders. Orders and payments from, or on behalf of, subscribers in the various geographical areas shown below should be sent to the office indicated.

The Americas: Oxford University Press, Distribution and Information Systems, 2001 Evans Road, Cary, North Carolina 27513; USA

Japan: available from the following agents: **Kinokuniya Company Ltd**, Journal Department, PO Box 55, Chitose, Tokyo, 156 Japan; **Maruzen Company Ltd**, Journal Division, PO Box 5050, Tokyo International 100-31 Japan; **Usaco Corporation**, 13-12, Shimbashi 1-chome, Minato-ku, Tokyo, 105 Japan.

Rest of World: Journals Subscriptions Department, Oxford University Press, Great Clarendon Street Oxford, OX2 6DP, UK

Tel: +44(0)1865 267907; fax +44(0)1865 267485; e-mail: jnl.orders@oup.co.uk

Advertising

To advertise in *Annals of Oncology*, contact Peter Carpenter, PRC Associates, The Annexe, Fitznells Manor, Chessington Road, Ewell Village, Surrey KT17 1TF.

Tel: +44(0)20 8786 7376; Fax: +44(0)20 8786 7262;

e-mail: mail@prcassoc.co.uk

Copyright

All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without either the prior written permission of the Publishers, or a licence permitting restricted copying issued in the UK by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P 9HE, or in the USA by the Copyright Clearance Centre, 222 Rosewood Drive, Danvers, MA 01923. Special requests, such as copying for general distribution or for advertising or promotional purposes, should be addressed to the Production Editor, *Annals of Oncology*, Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK.

Annals of Oncology (ISSN 0923-7534) is published monthly by Oxford University Press, Oxford UK. Annual subscription price is US\$1090.00.

Annals of Oncology is distributed by Mercury International, 365 Blair Road, Avenel, New Jersey, NY 07001, USA. Periodicals postage paid at Rahway, New Jersey and additional mailing entry points.

US Postmaster: send address changes to *Annals of Oncology*, c/o Mercury International, 365 Blair Road, Avenel, New Jersey, NY 07001, USA.

Journal disclaimer. All reasonable precautions have been taken by the authors, editors and publisher to verify drug names and doses, the results of experimental work and the clinical findings published in this journal. The opinions expressed are those of the authors, and not necessarily those of the editors or publisher. The ultimate responsibility for the use and dosage of drugs mentioned in *Annals of Oncology* and in the interpretation of published material lies with the medical practitioner. The editors and publisher can accept no liability whatsoever in respect of any claim for damages arising therefrom. Please inform the editors of any errors.

Summary of Conference Schedule

TUESDAY, JUNE 11, 2002

- 08:00 a.m. **OPENING OF THE REGISTRATION DESK**
- 01:30–05:30 p.m. **WORKSHOP “Primary CNS Lymphoma”** (*Room F*)
Chairmen: R. Rampling, Glasgow, UK and T. Batchelor, Boston, USA
(*by invitation only*)
- SATELLITE SYMPOSIA**
- 04:30 p.m.
(*parallel symposia*) Roche Ltd.:
MABTHERA®: REALISING THERAPEUTIC POTENTIAL (*Room A*)
Chairperson: S.J. Horning, Palo Alto, USA
- 04:30 p.m. Bio Envision Inc.:
NEW PERSPECTIVES IN B-CELL MALIGNANCIES (*Room BI*)
Chairman: M.J. Keating, Houston, USA
- 04:30 p.m. Amgen (Europe) AG:
**OPTIMISING HAEMATOPOIETIC CARE IN LYMPHOMA PATIENTS:
FOCUS ON THE ELDERLY** (*Room BIII*)
Chairman: D.C. Linch, London, UK
- 07:30 p.m.
(*parallel symposia*) Schering AG:
CONTROVERSIES IN THE MANAGEMENT OF FOLLICULAR LYMPHOMA
(*Room A*)
Chairmen: T.A. Lister, London, UK and F. Cavalli, Bellinzona, Ch
- 07:30 p.m. Baxter Oncology GmbH:
**ADVANCES IN THE MANAGEMENT OF RELAPSED AGGRESSIVE
NON-HODGKIN LYMPHOMA AND HODGKIN’S DISEASE** (*Room BI*)
Chairman: J.O. Armitage, Omaha, USA
- 07:30 p.m. Roche Ltd.:
ANAEMIA MANAGEMENT—SELECT, SUPPORT AND SUCCEED (*Room BIII*)
Chairman: J.F. San Miguel, Salamanca, Spain

WEDNESDAY, JUNE 12, 2002

- 07:00 a.m. **POSTER SET UP I** (*Marquee Parco Cianil/Congress Hall*)
- 07:30 a.m. **POSTER SESSION I** (*authors present—posters posted the whole day*)
- 09:00–09:45 a.m.
(*parallel sessions*) **MEET THE PROFESSOR—part I** (*Room A, BI, BIII, C, E, F*)
(*repetition Thursday, June 13, 2002, 07:00–07:45 a.m.*)
- 10:00–10:45 a.m.
(*parallel sessions*) **MEET THE PROFESSOR—part II** (*Room A, BI, BIII, C, E, F*)
(*repetition Friday, June 14, 2002, 07:00–07:45 a.m.*)

11:00–11:45 a.m. (parallel sessions)	POSTER DISCUSSIONS WITH DISCUSSION LEADERS POSTER SESSION I (<i>Rooms and sessions indicated in the pocket program</i>)
12:00–01:00 p.m.	LUNCH (<i>Marquee Parco Ciani</i>)
01:00 p.m.	OPENING OF THE CONFERENCE (<i>Room A/B</i>)
01:15 p.m.	AWARD OF THE SAN SALVATORE FOUNDATION (<i>Room A/B</i>)
01:30 p.m.	HENRY KAPLAN MEMORIAL LECTURE (<i>Room A/B</i>)
02:30–05:10 p.m.	SESSION 1—MOLECULAR HETEROGENEITY AND NEW TREATMENTS IN CLL (<i>Room A/B</i>)
05:30–06:30 p.m.	WORKSHOP I—WALDENSTRÖM'S MACROGLOBULINEMIA (<i>Room A/B</i>)

SATELLITE SYMPOSIA

07:30 p.m. (parallel sessions)	Schering AG/IDEC RADIOIMMUNOTHERAPY, A FIRST-IN-CLASS NOVEL THERAPY FOR THE TREATMENT OF LOW-GRADE NON-HODGKIN'S LYMPHOMA (<i>Room A</i>) Chairpersons: S.J. Horning, Palo Alto, USA and E. Montserrat, Barcelona, Spain
07:30 p.m.	Sanofi-Synthelabo: CRITICAL CASES IN LYMPHOMA CARE—AN INTERACTIVE DISCUSSION OF CASE STUDIES (<i>Room BI</i>) Chairmen: B. Coiffier, Pierre Bénite, France and M.J. Keating, Houston, USA

THURSDAY, JUNE 13, 2002

07:00–07:45 a.m.	MEET THE PROFESSOR (<i>repetition part I—same speakers, same rooms</i>)
07:00–08:00 a.m.	MEET THE EXPERT AT BREAKFAST (<i>locations and expert's names indicated in the pocket program; entrance by ticket only: tickets purchased at registration desk</i>)
08:00–09:50 a.m. (parallel session)	WORKSHOP II—BIOLOGY OF MARGINAL ZONE B-CELL LYMPHOMAS (<i>Room A</i>)
10:05–11:55 a.m. (parallel session)	WORKSHOP III—WHAT'S NEW IN MANTLE CELL LYMPHOMA? (<i>Room A</i>)
08:00–09:45 a.m.	SESSION 2—BIOLOGY OF LYMPHOMAS I (<i>Room B</i>)
10:05–11:50 a.m.	SESSION 3—BIOLOGY OF LYMPHOMAS II (<i>Room B</i>)
12:00–12:45 p.m.	KEY NOTE LECTURE I—MEMORY STEM CELLS (<i>Room A/B</i>)
01:00–02:00 p.m.	LUNCH (<i>Marquee Parco Ciani</i>)
02:00–03:45 p.m.	SESSION 4—REVIEW LECTURES (<i>Room A/B</i>)
04:00–05:45 p.m.	SESSION 5—THE INCREASING ROLE OF PROGNOSTIC FACTORS IN THE CHOICE OF TREATMENT (<i>Room A/B</i>)
05:45–06:30 p.m.	CONTROVERSY—IS THERE A ROLE FOR ALLO-TRANSPLANT IN ANY TYPE OF MALIGNANT LYMPHOMAS? (<i>Room A/B</i>)

SATELLITE SYMPOSIA

- 07:30 p.m.
(*parallel symposia*) Ligand Pharmaceuticals & Elan Pharmaceuticals:
PERIPHERAL T-CELL LYMPHOMAS: WHERE ARE WE? (*Room A*)
Chairpersons: J.M. Vose, Omaha, USA and F.M. Foss, Boston, USA
- 07:30 p.m. Lilly Oncology (Switzerland):
IS GEMZAR A NEW PARTNER IN LYMPHOMA TREATMENT? (*Room BI*)
Chairmen: V. Diehl, Cologne, D. and M. Ghielmini, Bellinzona, CH

FRIDAY, JUNE 14, 2002

- 07:00 a.m. **POSTER SET UP II** (*Marquee Parco Ciani/Congress Hall*)
- 07:30 a.m. **POSTER SESSION II** (*authors present—posters posted the whole day*)
- 07:00–07:45 a.m. **MEET THE PROFESSOR** (*repetition part II—same speakers, same rooms*)
- 07:00–08:00 a.m. **MEET THE EXPERT AT BREAKFAST**
(*locations and expert's names indicated in the pocket program;*
entrance by ticket only: tickets purchased at registration desk)
- 08:00–09:50 a.m. **SESSION 6—EPIDEMIOLOGY, IMAGING** (*Room A/B*)
- 10:05–11:55 a.m. **SESSION 7—MOLECULAR PATHOGENESIS OF MALIGNANT**
LYMPHOMAS: WHAT'S NEW? (*Room A/B*)
- 12:00–12:45 p.m. **KEY NOTE LECTURE II—JOHN ULTMANN MEMORIAL LECTURE**
(*Room A/B*)
- 01:00–02:00 p.m. **LUNCH** (*Marquee Parco Ciani*)
- 02:00–04:00 p.m. **SESSION 8—CLINICAL RESULTS IN LYMPHOMA I** (*Room A/B*)
- 04:15–06:30 p.m. **SESSION 9—CLINICAL RESULTS IN LYMPHOMA II** (*Room A*)
(*parallel session*)
- 04:00–06:45 p.m. **SESSION 10—PAEDIATRIC LYMPHOMAS** (*Room C*)
(*parallel session*)
- 04:15–06:30 p.m. **SESSION 11—CLINICAL PATHOLOGICAL CORRELATIONS** (*Room B*)
(*parallel session*)
- 06:30–07:15 p.m. **POSTER DISCUSSIONS WITH DISCUSSION LEADERS**
POSTER SESSION II (*Rooms and sessions indicated in the pocket program*)
- 07:15 p.m. **FAREWELL PARTY** (*Marquee Parco Ciani*)

SATURDAY, JUNE 15, 2002

- 08:00–11:15 a.m. **SESSION 12—NEW CHEMOTHERAPEUTIC AGENTS, NEW**
MODALITIES (*Room A*)
(*parallel session*)
- 08:30–10:10 a.m. **SESSION 13—BIOLOGICAL THERAPIES** (*Room B*)
(*parallel session*) Chairpersons: F.K. Stevenson and T.A. Lister

08:30–10:30 a.m.
(*parallel session*)

SESSION 14—EXTRANODAL LYMPHOMAS (*Room C*)
Chairmen: E. Zucca and P. Johnson

10:50 a.m.

CLOSING REMARKS in Room A
J.O. Armitage, Omaha, USA

11:15 a.m.

CLOSE

01:00–05:00 p.m.

**V. ANNUAL MEETING OF THE INTERNATIONAL EXTRANODAL
LYMPHOMA STUDY GROUP (IELSG)** (*Room B1*)